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Abstract
Introduction
The blood test for high-sensitivity cardiac troponin T (HS-CTnT) has been proposed as a
marker of cardiovascular risk in the general population, as it is associated with subsequent
incidence of cardiovascular events and mortality. We aimed at evaluating the feasibility of
HS-CTnT testing within large nationally-representative population surveys in which blood
samples are collected during household visits, shipped using the standard civil postal ser-
vice, and then frozen for subsequent analyses.
Methods
The Health Survey for England (HSE) consists of a series of annual surveys beginning in
1991. It is designed to provide regular information on various aspects of the nation’s health
and risk factors. We measured HS-CTnT in the blood of 200 people from the HSE 2016
wave, then froze and stored their blood samples at -40˚C for 5–10 weeks, and then thawed
and retested them to appreciate the extent of within-person agreement or test-retest reliabil-
ity of the two measurements.
Results
The Cronbach’s Alpha (Scale Reliability Coefficient) and the Interclass Correlation Coeffi-
cient (two-way mixed-effects model for consistency of agreement at individual level) were
0.97 (95%CI = 0.96–0.99) and 0.95 (95%CI = 0.94–0.96) respectively. The time delay from
blood withdrawal to analysis and storage (1–4 days) did not affect the results, nor did the
freezing time before the retest (5–10 weeks).
Conclusion
The measurement of HS-CTnT plasma concentration within large nationally-representative
surveys such as the Health Survey for England is feasible.
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Introduction
Cardiac troponin is a protein operating within the heart muscle cell. During a heart attack
(acute myocardial infarction) these cells rupture and troponin spills out into the main blood
stream; troponin can be detected in the peripheral venous blood as a marker of cardiac dam-
age. Cardiac troponin is the gold standard biomarker for diagnosing patients with heart attack
in acute clinical settings.[1] High-sensitivity assays have recently been developed and the tro-
ponin subunit T (HS-CTnT) has shown the highest epidemiological sensitivity.[2,3] With the
advent of high-sensitivity assays, troponin positivity has become a common finding even in
individuals free from cardiovascular symptoms and even outside clinical settings, possibly due
to leakage through the membranes of partially-damaged heart cells or due to some other
unknown mechanism.[4] In healthy people, HS-CTnT positivity is associated with greater sub-
sequent incidence of cardiovascular disease and mortality and can therefore be considered as
the most proximal sentinel marker of heart disease and an index of cardiovascular health.[5,6]
For these reasons, the testing for plasma HS-CTnT has been proposed as a marker of car-
diovascular risk in the general population and some large studies have already been conducted
using that marker at population level.[6,7] HS-CTnT elevation in healthy people has also been
studied in association with socioeconomic conditions using stored blood samples.[8–11]
However, the HS-CTnT assay was designed for hospital use and may be inadequate for pop-
ulation surveys, as in hospitals the test is carried out in emergency settings and the blood sam-
ples are analysed immediately after the blood withdrawal, whereas in population surveys the
blood is not analysed immediately and it is often frozen for subsequent analyses.
We aimed at evaluating the feasibility of HS-CTnT testing within nationally-representative
population surveys such as the Health Survey for England, in which blood samples are col-
lected during household visits, shipped using the standard civil postal service, centrifuged and
then the serum is frozen for subsequent analyses.
Methods
Study design
The Health Survey for England (HSE) is a nationally representative, general population-
based study that recruits individuals living in private households in England using stratified
random sampling.[12] The HSE consists of a series of annual surveys beginning in 1991 and
it is designed to provide regular information on various aspects of the nation’s health and
risk factors.[12,13] All HSE years have the same core measurements but each survey year
also has special focus topics that change from one year to another (e.g. cardiovascular disease
[CVD], accidents, respiratory conditions, kidney disease, etc.). The HSE blood samples are
collected by trained nurses during household visits, and then posted immediately using spe-
cial preformed, thin, absorbent packaging within printed leakproof bags to the laboratory for
biochemical analysis using first class Royal Mail. Once arrived at the laboratory, blood sam-
ples from the plain vacutainer tube (no preservative or anticoagulant) are centrifuged and
the serum is analysed; residual serum from participants who had given written consent is
then stored at -40˚C.[12] Ethical approval for HSE 2016–2019 was obtained from the East
Midlands Research Ethics Committee (reference no. 15/EM/0254). Study participants gave
fully-informed written consent.
Data collection
We analysed HS-CTnT in the blood of 200 people from the 2016 HSE wave. The collection of
blood samples took place between 28 June and 4 August 2016. The average temperature in that
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period of time in England was 16.7˚C (Min 12.3 –Max 21.1). The serum samples were frozen
and stored for 5–10 weeks, and then thawed and retested to appreciate the extent of within-
person agreement or test-retest reliability of the two measurements. There is a time delay from
the blood draw to the arrival of the samples at the laboratory, and in order to check if the delay
affects the test results or not, we set out to measure HS-CTnT on 50 random samples in each
‘delay category’ (day 1, 2, 3, and 4). We also checked if freezing time affects the test results or
not by retesting a third of each delay category after 5 to 7 weeks, 8–9 weeks, and at 10 weeks.
Data analysis
We carried out statistical analyses using several approaches. We compared the test results
between the original and frozen samples at individual level using the Cronbach’s Alpha (Scale
Reliability Coefficient) and the Interclass Correlation Coefficient (two-way mixed-effects
model for consistency of agreement at individual level).[14] The confidence interval for the
Cronbach’s Alpha was calculated using bootstrapping (1,000 replications).
We then recoded the crude values to label the study participants as being at low or high risk
(binary variable). We carried out this kind of analysis three times, each time applying a differ-
ent cut-off value: first at 3 ng/L, which is the lower limit of detection of the assay; then at 10ng/
L, which corresponds to the 90th percentile in our dataset; and finally at 14 ng/L, which corre-
sponds to the 95th percentile in our dataset and is also a recognised threshold to mark elevated
levels.[1,5,7] We then used the Kappa statistics to compare the extent of agreement between
the original and frozen measures for each of the three thresholds.
As a sensitivity analysis, HS-CTnT was log-transformed (before the transformation, zero
values were recoded to 1.5 ng/L, which equals the half of the lowest detection limit of the
assay). All computations were made using Stata v.14.2.
Results
There was only one missing value due to insufficient blood sample and the final analytic sam-
ple therefore included 199 observations. HS-CTnT was detectable (3 ng/L) in 29.0% of the
original samples (95%CI = 22.9–36.0) and in 28.1% of the frozen sample (95%CI = 22.0–34.9).
Table 1 shows a comparison of HS-CTnT findings between the original and frozen blood
samples.
The test-retest reliability between the original and frozen sample gave the following results:
Cronbach’s alpha = 0.97 (95%CI = 0.96–0.99); ICC = 0.95 (95%CI = 0.94–0.96).
Table 2 shows the Cronbach’s alpha and the ICC across categories of time delay (from
blood withdrawal to analysis) and of freezing time (from start of storage to thaw and retest).
The coefficients from these analyses were also close to 1 (perfect consistency).
Table 3 shows the results of the kappa statistics for the three cut-off points. The most effi-
cient cut-off point was 10 ng/L (K = 0.91, 95%CI = 0.83–1.00), although the other cut-off
points also showed evidence of very good agreement between original and frozen samples.
Discussion
Our results indicate that measuring HS-CTnT within population studies such as the Health
Survey for England is feasible, and that the analysis of blood samples stored for several weeks
at -40˚C gives consistent results compared to the analysis of original (although delayed) sam-
ples, with statistical results close to perfection.
In the HSE, nurses collect blood samples during household visits and then ship them
using the standard civil postal service. Therefore, samples may stay at room/external temper-
ature for 1–4 days before reaching the laboratory for analysis and storage and this may add
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inaccuracy to the analyses. However, although HS-CTnT should be analysed immediately
after blood withdrawal, there is evidence that HS-CTnT is stable for at least 24 h in whole
blood at room temperature.[15] In that study, blood samples were centrifuged after storage
at room temperature (20–23˚C) for 15 min, 4, 8, and 24 h. All HS-CTnT results in each series
were in a range from –3.9% to +2.5% compared with the results at 15 min. This was within
what was expected due to assay imprecision. Such stability was consistent across time delays,
and there was no trend showing increasing instability with increasing time delay. It is there-
fore likely that hypothetical enzymatic or non-enzymatic processes that do not affect
HS-CTnT detection within 24 h are also not operating in the subsequent hours. Moreover,
two more recent studies reported that HS-CTnT testing is not affected by preanalytical varia-
tion in type of blood collection tube, prolonged transport, centrifugation time and speed,
and storage conditions.[16,17]
Table 2. Cronbach’s Alpha (Scale Reliability Coefficient) and the Interclass Correlation Coefficient
(two-way mixed-effects model for consistency of agreement at individual level) for the test-retest reli-
ability between original and frozen samples for 199 individuals drawn from the Health Survey for
England, United Kingdom, in year 2016.
Subgroup N Type of comparison
Cronbach’s Alpha (95%CI) ICC (95%CI)
Delay days = 1 50 0.98 (0.96 to 1.00) 0.96 (0.93 to 0.98)
Delay days = 2 50 0.96 (0.92 to 1.01) 0.93 (0.88 to 0.96)
Delay days = 3 50 0.92 (0.84 to 1.01) 0.85 (0.75 to 0.91)
Delay days = 4 49 0.99 (0.96 to 1.01) 0.97 (0.95 to 0.98)
Freezing weeks <8 63 0.98 (0.97 to 1.00) 0.97 (0.95 to 0.98)
Freezing weeks = 8–9 77 0.98 (0.94 to 1.01) 0.96 (0.93 to 0.97)
Freezing weeks = 10 59 0.97 (0.94 to 0.99) 0.93 (0.89 to 0.96)
Whole sample 199 0.97 (0.96 to 0.99) 0.95 (0.94 to 0.96)
Delay days = number of days from blood withdrawal to analysis and storage of original blood samples.
Freezing weeks = number of weeks during which samples were kept frozen at −40˚C before thaw and retest.
doi:10.1371/journal.pone.0171242.t002
Table 1. High-sensitivity cardiac troponin T measurements for 199 individuals drawn from the Health
Survey for England 2016.
HS-CTnT Type of blood sample
Original Frozen
Detectable n (%) 58 (29.1) 56 (28.1)
Elevated n (%) 11 (5.5) 10 (5.0)
Minimum value if detectable ng/L 5 5
Maximum value if detectable ng/L 38 27
Arithmetic mean ± SD if detectable ng/L 10.4 ±5.6 9.8 ±4.5
Geometric mean ± SD if detectable ng/L 9.4 ±1.5 9.0 ±1.5
Median ± IQR if detectable ng/L 9.5 ±5.0 9.0 ±6.0
90th Percentile for the whole sample ng/L 10.0 10.0
95th Percentile for the whole sample ng/L 14.0 14.0
99th Percentile for the whole sample ng/L 26.0 25.0
Detectable concentrations are those3 ng/L. Elevated concentrations are those14 ng/L. SD = standard
deviation. IQR = interquartile range.
doi:10.1371/journal.pone.0171242.t001
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However, our results may not be generalizable to countries where the external temperature
is much higher than in England, as protein denaturation may happen with the elevated exter-
nal temperatures that are reached in some countries.
In acute settings, the diagnosis of a heart attack is centred on HS-CTnT test findings above
the arbitrary threshold value of 14.0 ng/L,[2] corresponding to a value of HS-CTnT at the 99th
percentile that was derived from small studies of presumably healthy individuals, with rela-
tively little phenotypic characterisation, and not representing the English population. There is
evidence that the value of cardiac troponin blood concentration at the 99th percentile differs
according to demographic and clinical conditions.[2,18] In this study, we found a value of
HS-CTnT at the 99th percentile of 25 ng/L. Therefore using 14 ng/dL as a cut-off point to flag
people with a heart attack in English hospitals may lead to false-positive diagnoses. However,
although the HSE is a nationally-representative survey, we carried out our analyses on a sub-
sample of that survey, and therefore our sample may not be representative of the English popu-
lation. Variables such as age, gender, location, and other demographic and clinical variables
were not available for analysis and we therefore could not study them in relation to HS-CTnT.
Furthermore we cannot exclude the possibility that some of our participants had heart disease.
Therefore we encourage further research in estimating population percentiles for HS-CTnT,
as has also been suggested by a recent NICE guideline (National Institute for Health and Care
Excellence).[2]
Now that we have shown that the measurement of HS-CTnT plasma concentration within
nationally-representative surveys such as the Health Survey for England is feasible, there may
be several possible applications of HS-CTnT surveys. The HS-CTnT percentiles may vary
according to clinical and demographic population conditions, and therefore we encourage the
development of nationally representative, nation-specific population surveys to calculate
nation-specific thresholds of HS-CTnT for the diagnosis of a heart attack within each health-
care system. Another objective could be to map the prevalence of HS-CTnT positivity at
regional, national and international level and in population sub-groups, to identify the areas of
the world or the population subgroups that are at higher risk of heart disease. The traditional
risk factors for CVD that are measured in population surveys are not sufficient to explain the
burden of CVD in the world. This is because risk factors such as blood pressure and cholesterol
are unable to fully explain the development of atherosclerosis and thrombosis, and atheroscle-
rosis and thrombosis are not the only precursors of CVD.[9] By being a more proximal marker
for CVD and an alert signal prior to CVD events, HS-CTnT positivity incorporates and inte-
grates the effects of the other more distal risk factors. HS-CTnT is therefore a good candidate
to become a useful marker of cardiovascular health that could be used at a population level.
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Table 3. Kappa statistics for the agreement between original and frozen HS-CTnT samples in flagging
high-risk individuals using different cut-off points, for 199 participants drawn from the Health Survey
for England, United Kingdom, in year 2016.
Cut-off Kappa (95%CI)
3 ng/L 0.88 (0.80 to 0.95)
10 ng/L 0.91 (0.83 to 1.00)
14 ng/L 0.85 (0.68 to 1.00)
doi:10.1371/journal.pone.0171242.t003
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